Genmab — Juni 2016
-
Novod siger MS markedet er USD 20bn+. Så er USD 2,5bn til "best-in-class" ikke højt.

-
det er nok lidt tidligt ifht asco

-
@Sukkeralf: "Roche's infusion based CD20 antibody ocrelizumab is on the way to the market in both RRMS and PPMS with peak sales for that drug estimated to be above USD 5bn."
-
Det var quote fra Novod
-
Tak for link MUFC.

-
hmm - draghi fik vist pillet pynten af markedet...
-
@Helge og Bulder. Hvad der slog mig, var han nævnte elotuzumab et par gange. Men alle ved jo at daratumumab er bedre!
-
i skal lige have in mente, at når onkologer udtaler sig, så handler det om medikamenter, der ER godkendte. Det er meget sjældent at de har ting i klinikken i kikkerten
-
Enig med Bulder.
-
Jeps, det siger vores CEO. Så må vi tro på det.
-
enig Bulder
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind